Introduction

The Fleming Fund (FF) is a U.K. Department of Health and Social Care programme to help low- and middle-income countries fight Antimicrobial Resistance (AMR). AMR poses a severe global threat, expected to cause 10 million deaths annually by 2050. With potential costs reaching $100 trillion, its impact on the global economy is significant. Fleming Fund Grants aim to tackle the AMR challenge in developing countries including Pakistan. The grants are funded by the UK Department of Health and Social Care and managed by Mott MacDonald for the country, regional and fellowship grants. Pakistan has received Fleming Fund support since 2019 in the form of two Country Grants, 9 Fellowships, and central and local procurement of equipment, reagents, and consumables. Between 2017 and the end of phase-1 of the program in March 2023, the program has provided financial support to grantees to establish and support local development of national AMR surveillance systems.

In partnership with the Fleming Fund, DAI's programme in Pakistan collaborates with the Pakistani government to strengthen systems using a “One Health” approach – a multisectoral approach to complex health problems that reaches across human health, animal health, and environment sectors. As global leaders in One Health, the DAI team helps incorporate One Health across programme interventions. DAI is helping Pakistan become a leader in combating antimicrobial resistance, and a model for better management of antimicrobials in human and animal populations. DAI and its consortium partnershave successfully secured an additional round, Phase 2, of the Fleming Fund Country Grant in Pakistan which spans from January 2024 to December 2025. The Phase 2 of the FFCG programme focuses on achieving four intermediate outcomes: 1) Production of quality AMR/U/C and burden of disease data; 2) Conducting quality data analysis; 3) Sharing quality data analysis with decision-makers; and 4) Contributing to sustainable investments at both the country and global levels to counter AMR.

Position Summary

Fleming Fund CG requires a WHONET / Antibiogram expert to implement a subcomponent of the activity Report showing significant progress of all FF-supported labs towards the attainment of core level and support the activity. Annual national antibiogram produced which at national level is supported by Liverpool School of Tropical Medicine (LSTM).

Major Responsibilities

• Ensure accurate and timely data entry on WHONET software and provide comprehensive support to all selected hospitals to enhance antimicrobial resistance (AMR) surveillance data quality and analysis.
• Regularly review and verify data quality, correcting errors and inconsistencies in the data entry process.
• Train designated hospital staff on using WHONET correctly, focusing on data entry protocols, data integrity, and basic troubleshooting.
• Develop training needs assessment for selected hospitals specifically to WHONET and data entry to be shared with the country office for training material development.
• Provide on-site and virtual technical support to hospital staff for any issues related to WHONET, including software installation, troubleshooting, and updates.
• Assist in generating regular reports from WHONET for internal use and compliance with national and international surveillance requirements.
• Support hospitals in interpreting data outputs and guide how to utilise data for quality improvement initiatives.
• Travel to the other sites as and when required.

Requirements (Education, Experience, Skills, Languages etc.)

• Bachelor's in clinical microbiology/medical laboratory technology. A candidate with a strong background in IT will be preferred.
• Minimum three years of proven experience in antibiogram development (WHONET) and general data analytics
• Good written and spoken English and Urdu